by Raynovich Rod | Aug 20, 2024 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Update-2 8/26/24….On a 3 day weekend so no new post till Wednesday. It’s a quiet week with many people taking off before Labor Day weekend. Some big SMID movers today so check them out: CRMD up over 9% , DNLI up 3.31%, IMTX up over 3%, RZLT up 8%, All...
by Raynovich Rod | Jul 8, 2024 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-3 …7/11…SMID biotechs rally on a big rotation day out of MEGA Cap tech.XBI up 2.67% “kissing” the $98 level.Nibble on our Life Science trading list as it is another “green screen ” day. Even the IBB broke through $140 today...
by Raynovich Rod | Jun 10, 2024 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Healthcare stocks
Update-4…6/29….I’m back but I did not miss much in biotech trades, but a lot of “3 day wonders'” you know stocks that get momentum then quickly fade. The XBI is still holding above the $90 support level with a range of $89.13 to $94.88...
by Raynovich Rod | Jun 3, 2024 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 Biopharma rally moves to SMID caps as momentum picks up ADPT, NVAX, TWST etc XBI over $93. Large caps steady with REGN over $1000. POST ASCO large cap core portfolio picks: ABBV, AZN, LLY, MRK, REGN. VRTX. Pfizer had good results but the stock could not...
by Raynovich Rod | Feb 20, 2024 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-1 2/23/24. You know the story by now it’s all about AI and NVDA. As my friend said in the mid -90s “there is no end to chips Rod”. Overall one of the best weeks for the market but of course led by technology stocks. The equal weight small cap...
by Raynovich Rod | Feb 12, 2024 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1..2/15/24…Post from 9/23 biotech bottom when we picked ABBV,GEHC. Near/at new 52 wk. highs : ABBV, LLY, MRK, VRTX, XPH etc. Update- -2/12/24….Gilead Sciences responds immediately to recent trial disappointment to buy CymaBay,a $4.3B deal expanding...
by Raynovich Rod | Jan 7, 2024 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Large Cap Biopharmaceuticals as of 1/7/24 prior to JPM Most healthcare ETFs and Large Caps are up since the 10/8/23 lows. We will look at these valuations after JPM and Q4 earnings.The trend for the Life Science and Biopharma sector is usually up for Q4 in...
by Raynovich Rod | Dec 4, 2023 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biden vs Biopharmaceutical industry: “March in on Patents”.. https://x.com/PeterKolchinsky/status/1732852724675273103?s=2 Will the Administration take back licensing rights with government funded research to control drug prices? ======= ASH this past week....
by Raynovich Rod | Oct 16, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 10/20 Merck (MRK) pops over 2% to $102+ on ADC deal with Daiichi Sankyo. Collaboration combines Daiichi Sankyo’s proven ADC expertise and DXd technology with Merck’s deep experience in oncology and clinical development capabilities to advance and expand the...
by Raynovich Rod | Oct 9, 2023 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Update-4 10/17…JNJ now reporting as a stand-alone biopharmaceutical and medical device Company raised its profit forecast helped by demand from it anti-inflammatory drug Stelara and reported a gain of $21 B from the spin-off of its consumer health unit Kenvue....
